Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 1892 results for carers

  1. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]

    In development [GID-TA10834] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  6. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  7. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Voxelotor for treating sickle cell disease [ID1403]

    In development [GID-TA10505] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  9. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  10. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  11. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  12. Depemokimab for treating chronic rhinosinusitis with nasal polyps TSID 12012

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]

    In development [GID-TA10883] Expected publication date: 18 September 2024

    Technology appraisal guidance
    In development

  14. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]

    In development [GID-TA11006] Expected publication date: 29 May 2024

    Technology appraisal guidance
    In development

  15. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 04 June 2024

    Technology appraisal guidance
    In development